125 related articles for article (PubMed ID: 30889615)
1. [Molecular pathology of prostate cancer].
Tímár J
Magy Onkol; 2019 Mar; 63(1):5-9. PubMed ID: 30889615
[TBL] [Abstract][Full Text] [Related]
2. Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally Metastatic Prostate Cancer.
Gong Y; Fan L; Fei X; Zhu Y; Du X; He Y; Pan J; Dong B; Xue W
J Urol; 2021 Aug; 206(2):279-288. PubMed ID: 33780283
[TBL] [Abstract][Full Text] [Related]
3. [Androgen receptor variants in prostate cancer].
Schreyer E; Barthélémy P; Cottard F; Ould Madi-Berthélémy P; Schaff-Wendling F; Kurtz JE; Céraline J
Med Sci (Paris); 2017; 33(8-9):758-764. PubMed ID: 28945566
[TBL] [Abstract][Full Text] [Related]
4. Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
Beltran H; Antonarakis ES; Morris MJ; Attard G
Am Soc Clin Oncol Educ Book; 2016; 35():131-41. PubMed ID: 27249694
[TBL] [Abstract][Full Text] [Related]
5. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
6. Basic Science and Molecular Genetics of Prostate Cancer Aggressiveness.
Schiewer MJ; Knudsen KE
Urol Clin North Am; 2021 Aug; 48(3):339-347. PubMed ID: 34210489
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
8. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
Del Re M; Crucitta S; Restante G; Rofi E; Arrigoni E; Biasco E; Sbrana A; Coppi E; Galli L; Bracarda S; Santini D; Danesi R
Crit Rev Oncol Hematol; 2018 May; 125():51-59. PubMed ID: 29650277
[TBL] [Abstract][Full Text] [Related]
10. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
11. Lineage plasticity in cancer: a shared pathway of therapeutic resistance.
Quintanal-Villalonga Á; Chan JM; Yu HA; Pe'er D; Sawyers CL; Sen T; Rudin CM
Nat Rev Clin Oncol; 2020 Jun; 17(6):360-371. PubMed ID: 32152485
[TBL] [Abstract][Full Text] [Related]
12. Biological Evolution of Castration-resistant Prostate Cancer.
Davies A; Conteduca V; Zoubeidi A; Beltran H
Eur Urol Focus; 2019 Mar; 5(2):147-154. PubMed ID: 30772358
[TBL] [Abstract][Full Text] [Related]
13. Molecular Subtypes of Prostate Cancer.
Arora K; Barbieri CE
Curr Oncol Rep; 2018 Jun; 20(8):58. PubMed ID: 29858674
[TBL] [Abstract][Full Text] [Related]
14. The molecular biology of prostate cancer: current understanding and clinical implications.
Gandhi J; Afridi A; Vatsia S; Joshi G; Joshi G; Kaplan SA; Smith NL; Khan SA
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):22-36. PubMed ID: 29282359
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives.
Hu J; Wang G; Sun T
Tumour Biol; 2017 May; 39(5):1010428317692259. PubMed ID: 28475016
[TBL] [Abstract][Full Text] [Related]
16. Loss of Wave1 gene defines a subtype of lethal prostate cancer.
Sowalsky AG; Sager R; Schaefer RJ; Bratslavsky G; Pandolfi PP; Balk SP; Kotula L
Oncotarget; 2015 May; 6(14):12383-91. PubMed ID: 25906751
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.
Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M
Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626
[TBL] [Abstract][Full Text] [Related]
18. TP53 structural variants in metastatic prostatic carcinoma.
Sirohi D; Devine P; Grenert JP; van Ziffle J; Simko JP; Stohr BA
PLoS One; 2019; 14(6):e0218618. PubMed ID: 31216325
[TBL] [Abstract][Full Text] [Related]
19. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam PJ; Van den Eynden G; Rutten A; Aly M; Nordström T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullén A; Yachnin J; Dirix L; Grönberg H; Lindberg J
Genome Med; 2018 Nov; 10(1):85. PubMed ID: 30458854
[TBL] [Abstract][Full Text] [Related]
20. Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies.
Friedlander TW; Pritchard CC; Beltran H
Am Soc Clin Oncol Educ Book; 2017; 37():358-369. PubMed ID: 28561699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
